Overview

  • Product nameAnti-Cytokeratin 1 antibody [AE1]
    See all Cytokeratin 1 primary antibodies
  • Description
    Mouse monoclonal [AE1] to Cytokeratin 1
  • SpecificityThis antibody recognises most of the acidic (Type 1) keratins.
  • Tested applicationsSuitable for: IHC-Fr, IHC-P, WBmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Rabbit, Chicken, Cow, Monkey, Turtle
  • Immunogen

    Epidermal keratin

Properties

Applications

Our Abpromise guarantee covers the use of ab9286 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr Use at an assay dependent concentration.
IHC-P 1/150 - 1/200.
WB 1/100. Predicted molecular weight: 67 kDa.

Target

  • FunctionMay regulate the activity of kinases such as PKC and SRC via binding to integrin beta-1 (ITB1) and the receptor of activated protein kinase C (RACK1/GNB2L1).
  • Tissue specificityThe source of this protein is neonatal foreskin. The 67-kDa type II keratins are expressed in terminally differentiating epidermis.
  • Involvement in diseaseDefects in KRT1 are a cause of bullous congenital ichthyosiform erythroderma (BCIE) [MIM:113800]; also known as epidermolytic hyperkeratosis (EHK) or bullous erythroderma ichthyosiformis congenita of Brocq. BCIE is an autosomal dominant skin disorder characterized by widespread blistering and an ichthyotic erythroderma at birth that persist into adulthood. Histologically there is a diffuse epidermolytic degeneration in the lower spinous layer of the epidermis. Within a few weeks from birth, erythroderma and blister formation diminish and hyperkeratoses develop.
    Defects in KRT1 are the cause of ichthyosis hystrix Curth-Macklin type (IHCM) [MIM:146590]. IHCM is a genodermatosis with severe verrucous hyperkeratosis. Affected individuals manifest congenital verrucous black scale on the scalp, neck, and limbs with truncal erythema, palmoplantar keratoderma and keratoses on the lips, ears, nipples and buttocks.
    Defects in KRT1 are a cause of palmoplantar keratoderma non-epidermolytic (NEPPK) [MIM:600962]. NEPKK is a dermatological disorder characterized by focal palmoplantar keratoderma with oral, genital, and follicular lesions.
    Defects in KRT1 are a cause of ichthyosis annular epidermolytic (AEI) [MIM:607602]; also known as cyclic ichthyosis with epidermolytic hyperkeratosis. AEI is a skin disorder resembling bullous congenital ichthyosiform erythroderma. Affected individuals present with bullous ichthyosis in early childhood and hyperkeratotic lichenified plaques in the flexural areas and extensor surfaces at later ages. The feature that distinguishes AEI from BCIE is dramatic episodes of flares of annular polycyclic plaques with scale, which coalesce to involve most of the body surface and can persist for several weeks or even months.
    Defects in KRT1 are the cause of palmoplantar keratoderma striate type 3 (SPPK3) [MIM:607654]; also known as keratosis palmoplantaris striata III. SPPK3 is a dermatological disorder affecting palm and sole skin where stratum corneum and epidermal layers are thickened. There is no involvement of non-palmoplantar skin, and both hair and nails are normal.
  • Sequence similaritiesBelongs to the intermediate filament family.
  • Post-translational
    modifications
    Undergoes deimination of some arginine residues (citrullination).
  • Cellular localizationCell membrane. Located on plasma membrane of neuroblastoma NMB7 cells.
  • Information by UniProt
  • Database links
  • Alternative names
    • 67 kDa cytokeratin antibody
    • CK-1 antibody
    • CK1 antibody
    • Cytokeratin-1 antibody
    • Cytokeratin1 antibody
    • EHK antibody
    • EHK1 antibody
    • Epidermolytic hyperkeratosis 1 antibody
    • EPPK antibody
    • Hair alpha protein antibody
    • K1 antibody
    • K2C1_HUMAN antibody
    • Keratin antibody
    • Keratin type II cytoskeletal 1 antibody
    • Keratin-1 antibody
    • Keratin1 antibody
    • KRT 1 antibody
    • Krt1 antibody
    • KRT1A antibody
    • NEPPK antibody
    • type II cytoskeletal 1 antibody
    • Type II keratin Kb1 antibody
    • Type-II keratin Kb1 antibody
    see all

Anti-Cytokeratin 1 antibody [AE1] images

  • ab9286 staining Cytokeratin 1 in rat normal skin tissue by Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections). Tissue was fixed with formaldehyde and a heat mediated antigen retrieval step was performed using 10mM citrate buffer pH 6.3. Samples were then blocked with 5% BSA for 20 minutes at 27°C followed by incubation with the primary antibody at a 1/100 dilution for 1 hour at 27°C. An HRP-conjugated goat polyclonal was used as secondary antibody undiluted.

References for Anti-Cytokeratin 1 antibody [AE1] (ab9286)

This product has been referenced in:
  • Spagnolo DV  et al. Monoclonal anti-keratin (AE1) reactivity in routinely processed tissue from 166 human neoplasms. Am J Clin Pathol 84:697-704 (1985). Read more (PubMed: 2416215) »
  • Sun TT  et al. Monoclonal antibody studies of mammalian epithelial keratins: a review. Ann N Y Acad Sci 455:307-29 (1985). Read more (PubMed: 2417518) »

See all 9 Publications for this product

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Turtle Tissue sections (normal skin)
Specification normal skin
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: 0.01M Citrate buffer pH6 30min
Permeabilization No
Blocking step BSA as blocking agent for 20 minute(s) · Concentration: 5% · Temperature: 27°C
Username

Abcam user community

Verified customer

Submitted Apr 19 2011

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Rat Tissue sections (normal skin)
Specification normal skin
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: 0.01M Citrate buffer pH6 30min
Permeabilization No
Blocking step BSA as blocking agent for 20 minute(s) · Concentration: 5% · Temperature: 27°C
Username

Abcam user community

Verified customer

Submitted Apr 15 2011

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"